Funding will support the Phase 2 clinical program of ATI-2173 in HBV Soleus Capital led the round with new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as Altium Capital, Amzak Health, Granite Point Capital Management, LP, and LifeSci Venture Partners and participating existing investors Lumira Ventures, Cam Capital, Delos Capital, Domain Associates and Sixty Degree Capital MENDHAM, N.J., April 12, 2021-- Antios Therapeutics, Inc. (“Antios”) today announced the successful completion of a $96 million Series B financing.